Microglial TREM2-SYK Pathway Enhancement

Target: TREM2 Composite Score: 0.798 Price: $0.74▲19.9% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🧠 Neurodegeneration 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🔬 Microglial Biology 🔮 Lysosomal / Autophagy

✓ All Quality Gates Passed

Quality Report Card click to collapse

B+

Composite: 0.798

Top 7% of 1374 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

A Mech. Plausibility 15% 0.80 Top 20%

B+ Evidence Strength 15% 0.70 Top 26%

B Novelty 12% 0.60 Top 74%

B+ Feasibility 12% 0.70 Top 31%

A Impact 12% 0.80 Top 22%

A Druggability 10% 0.80 Top 22%

B Safety Profile 8% 0.60 Top 36%

B+ Competition 6% 0.70 Top 39%

B+ Data Availability 5% 0.70 Top 31%

B+ Reproducibility 5% 0.70 Top 27%

Evidence

5 supporting | 3 opposing

Citation quality: 100%

Debates

1 session A+

Avg quality: 0.90

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain Cell Atlas? Identify mechanisms of cell-type-specific vulnerability in neurons, microglia, astrocytes, and oligodendrocytes. Focus on gene expression patterns, pathway dysregulation, and therapeutic implications.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia

Score: 0.847 | Target: ACSL4

40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia

Score: 0.801 | Target: ACSL4

ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degeneration in Alzheimer's Disease

Score: 0.801 | Target: ACSL4

ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease

Score: 0.779 | Target: ACSL4

LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine in Disease-Associated Microglia

Score: 0.779 | Target: LPCAT3

ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidation

Score: 0.777 | Target: ALOX15

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia

Score: 0.776 | Target: LPCAT3

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Microglia

Score: 0.770 | Target: LPCAT3

→ View full analysis & all 9 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Microglial TREM2-SYK Pathway Enhancement in Neurodegeneration ### Mechanistic Basis The triggering receptor expressed on myeloid cells 2 (TREM2) is a surface receptor predominantly expressed on microglia and other tissue-resident macrophages. Extensive genetic evidence ties TREM2 to Alzheimer's disease risk — loss-of-function mutations (e.g., TREM2 R47H) approximately double AD risk, demonstrating that tonic TREM2 signaling is neuroprotective. The TREM2-SYK axis represents the primary intracellular signaling cascade downstream of TREM2 activation. Upon ligand binding (including lipids, phospholipids, APOE, and Aβ oligomers), TREM2 recruits SYK (spleen tyrosine kinase) via its intracellular ITAM domain. Activated SYK phosphorylates downstream intermediates including PLCγ2, CARD9, and the PI3K-AKT-mTOR axis. This signaling cascade orchestrates a transcriptional program that converts resting microglia into disease-associated microglia (DAM) or TREM2-independent checkpoints. DAM microglia demonstrate enhanced phagocytic capacity for amyloid-β, myelin debris, and dead neurons, while also adopting an anti-inflammatory transcriptional profile. ### Therapeutic Rationale The core hypothesis is that pharmacological enhancement of TREM2-SYK signaling in its early-stage deficit state — before microglial senescence sets in — will restore neuroprotective microglial functions and slow neurodegeneration. Multiple complementary strategies can achieve this: 1. TREM2 Agonist Antibodies: Monoclonal antibodies designed to bind the extracellular domain of TREM2 with agonistic properties (mimicking natural ligand-induced clustering) represent the most direct approach. Unlike the neutralization approach taken with anti-Aβ antibodies, these would amplify existing protective signaling. However, antibody brain penetration remains a major obstacle, necessitating the development of bispecific antibodies or ligand-directed delivery systems. 2. SYK Small-Molecule Activators: Direct SYK activation bypasses the TREM2 receptor entirely, offering potential for more uniform pathway engagement. However, SYK is ubiquitously expressed across immune cells, raising concerns about off-target immune activation. Selective SYK modulators that spare the kinase domain but enhance scaffolding functions may reduce this risk. 3. TREM2 Ligand Decoys: Soluble TREM2-Fc fusion proteins compete for TREM2 ligands, generating clustered TREM2 complexes that act as decoy receptors — simultaneously amplifying signaling and sequestering ligands that might otherwise act as partial antagonists. 4. PLCγ2 Activation: PLCγ2 is the primary effector downstream of SYK in the TREM2 cascade. Direct PLCγ2 agonists would engage the pathway at the first intracellular node, potentially offering more selective microglial effects. ### Clinical Evidence and Challenges A critical tension in this therapeutic area is the apparent paradox that TREM2 loss-of-function variants cause neurodegeneration, yet chronic over-activation may also be detrimental. The relationship between TREM2 signaling intensity and therapeutic benefit appears to be an inverted U-shaped curve — insufficient signaling causes microglial failure, while excessive signaling may drive hyperactivation and pathological synapse loss. This suggests biomarker-guided dosing is essential. Single-cell RNA sequencing of AD brains reveals that TREM2-expressing microglia occupy a transitional zone between homeostatic and DAM states. In early disease, these microglia retain plasticity and could be pushed toward the neuroprotective DAM phenotype through targeted TREM2 agonism. In late disease, microglial energy failure and metabolic collapse may render the TREM2-SYK axis unresponsive regardless of pharmacological stimulation. ### Biomarker Considerations CSF GFAP and NfL levels may serve as pharmacodynamic biomarkers of microglial activation. Increases in GFAP (reflecting astrocyte reactivity) and decreases in NfL (reflecting reduced neuronal loss) would constitute early signals of TREM2-SYK pathway activation. PET imaging with microglial tracers (TSPO) could provide in vivo confirmation of the microglial state shift. ### Evidence Summary Supporting evidence demonstrates: (1) TREM2 R47H variant carriers show reduced microglial phagocytosis and increased amyloid accumulation (Nature 2023, PMID 36306735); (2) ACE-driven microglial activation enhances SYK signaling and Aβ clearance (J Neuroinflammation 2024, PMID 38712251); (3) anti-TREM2 antibodies reduce amyloid plaque burden in 5XFAD mice (MAbs 2022, PMID 35921534); (4) TREM2-dependent microglial states are dysregulated across multiple brain regions in AD (Nature Neuroscience 2024, PMID 39048816). Counter-evidence includes: (1) non-linear dose-response relationships complicating therapeutic window definition; (2) enhanced phagocytosis risks clearing beneficial synaptic elements; (3) microglial states show substantial regional heterogeneity not captured by bulk measurements; (4) TSPO PET signals may reflect multiple microglial activation programs simultaneously, complicating interpretation." Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating TREM2 or the surrounding pathway space around TREM2/TYROBP microglial signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.60, feasibility 0.70, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `TREM2` and the pathway label is `TREM2/TYROBP microglial signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context TREM2: - TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a lipid-sensing immunoreceptor on microglia that signals through TYROBP/DAP12 to promote phagocytosis while suppressing inflammation. Allen Human Brain Atlas shows exclusive microglial expression with highest density in hippocampus, temporal cortex, and around amyloid plaques. Disease-associated microglia (DAM) are defined by TREM2-high/P2RY12-low expression. SEA-AD data shows TREM2 upregulation (log2FC=+1.5) correlating with Braak stage. Two-stage DAM model: Stage 1 (TREM2-independent) involves downregulation of homeostatic genes; Stage 2 (TREM2-dependent) involves phagocytic gene upregulation (CLEC7A, AXL, LGALS3). R47H variant (OR=2.9-4.5 for AD) reduces ligand binding by ~50%; sTREM2 (soluble) is shed by ADAM10/17 and serves as CSF biomarker. - Allen Human Brain Atlas: Exclusively microglia; highest in hippocampus, temporal cortex, and around amyloid plaques; BAMs also express TREM2 - Cell-type specificity: Microglia (highest, exclusive in CNS), Border-associated macrophages (BAMs), Not expressed in neurons, astrocytes, or oligodendrocytes under homeostatic conditions - Key findings: TREM2-high microglia form physical barrier around dense-core plaques, compacting cores and limiting oligomer diffusion; TREM2 R47H variant (OR=2.9-4.5 for AD) reduces PS/lipid binding by ~50%; sTREM2 in CSF peaks at clinical conversion from MCI to AD, serving as microglial activation biomarker This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TREM2 or TREM2/TYROBP microglial signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains. Identifier 39048816. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance. Identifier 38712251. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Identifier 36306735. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. Identifier 35921534. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. Identifier 37099634. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Knock-in models show complex microglial-synapse relationship that does not uniformly support enhancement therapy. Identifier 34266459. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Microglia-mediated neuroinflammation shows context-dependent effects that complicate targeted intervention. Identifier 35642214. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic target states. Identifier 36327895. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.745`, debate count `1`, citations `8`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Microglial TREM2-SYK Pathway Enhancement". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting TREM2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating TREM2 or the surrounding pathway space around TREM2/TYROBP microglial signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.70, novelty 0.60, feasibility 0.70, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `TREM2` and the pathway label is `TREM2/TYROBP microglial signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context TREM2: - TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a lipid-sensing immunoreceptor on microglia that signals through TYROBP/DAP12 to promote phagocytosis while suppressing inflammation. Allen Human Brain Atlas shows exclusive microglial expression with highest density in hippocampus, temporal cortex, and around amyloid plaques. Disease-associated microglia (DAM) are defined by TREM2-high/P2RY12-low expression. SEA-AD data shows TREM2 upregulation (log2FC=+1.5) correlating with Braak stage. Two-stage DAM model: Stage 1 (TREM2-independent) involves downregulation of homeostatic genes; Stage 2 (TREM2-dependent) involves phagocytic gene upregulation (CLEC7A, AXL, LGALS3). R47H variant (OR=2.9-4.5 for AD) reduces ligand binding by ~50%; sTREM2 (soluble) is shed by ADAM10/17 and serves as CSF biomarker. - Allen Human Brain Atlas: Exclusively microglia; highest in hippocampus, temporal cortex, and around amyloid plaques; BAMs also express TREM2 - Cell-type specificity: Microglia (highest, exclusive in CNS), Border-associated macrophages (BAMs), Not expressed in neurons, astrocytes, or oligodendrocytes under homeostatic conditions - Key findings: TREM2-high microglia form physical barrier around dense-core plaques, compacting cores and limiting oligomer diffusion; TREM2 R47H variant (OR=2.9-4.5 for AD) reduces PS/lipid binding by ~50%; sTREM2 in CSF peaks at clinical conversion from MCI to AD, serving as microglial activation biomarker This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TREM2 or TREM2/TYROBP microglial signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains. Identifier 39048816. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance. Identifier 38712251. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Identifier 36306735. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. Identifier 35921534. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. Identifier 37099634. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Knock-in models show complex microglial-synapse relationship that does not uniformly support enhancement therapy. Identifier 34266459. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Microglia-mediated neuroinflammation shows context-dependent effects that complicate targeted intervention. Identifier 35642214. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic target states. Identifier 36327895. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.745`, debate count `1`, citations `8`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Microglial TREM2-SYK Pathway Enhancement".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TREM2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["TREM2 Receptor"] -->|"ligand binding"| B["Phospholipid and ApoE Ligands"]
    B -->|"receptor activation"| C["TYROBP/DAP12 Phosphorylation"]
    C -->|"ITAM signaling"| D["SYK Kinase Activation"]
    
    D -->|"downstream cascade"| E["PI3K-AKT Pathway"]
    E -->|"metabolic switch"| F["Microglial Reprogramming"]
    F -->|"enhanced function"| G["Phagocytic Capacity"]
    G -->|"clearance"| H["Amyloid Beta Removal"]
    
    E -->|"anti-inflammatory"| I["Reduced Cytokine Production"]
    F -->|"homeostatic state"| J["Microglial Survival"]
    
    K["TREM2 Loss-of-Function"] -->|"impaired signaling"| L["Disease-Associated Microglia"]
    L -->|"dysfunction"| M["Reduced Phagocytosis"]
    L -->|"inflammation"| N["Pro-inflammatory State"]
    M -->|"accumulation"| O["Amyloid Pathology"]
    N -->|"damage"| P["Neurodegeneration"]
    
    Q["TREM2 Enhancement Therapy"] -->|"pathway activation"| D
    Q -->|"restoration"| F

    style A fill:#ce93d8,stroke:#fff,color:#000
    style B fill:#ce93d8,stroke:#fff,color:#000
    style C fill:#ce93d8,stroke:#fff,color:#000
    style D fill:#4fc3f7,stroke:#fff,color:#000
    style E fill:#4fc3f7,stroke:#fff,color:#000
    style F fill:#4fc3f7,stroke:#fff,color:#000
    style G fill:#81c784,stroke:#fff,color:#000
    style H fill:#81c784,stroke:#fff,color:#000
    style I fill:#81c784,stroke:#fff,color:#000
    style J fill:#81c784,stroke:#fff,color:#000
    style K fill:#ef5350,stroke:#fff,color:#000
    style L fill:#ef5350,stroke:#fff,color:#000
    style M fill:#ef5350,stroke:#fff,color:#000
    style N fill:#ef5350,stroke:#fff,color:#000
    style O fill:#ef5350,stroke:#fff,color:#000
    style P fill:#ffd54f,stroke:#fff,color:#000
    style Q fill:#81c784,stroke:#fff,color:#000

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

8 citations 8 with PMID 5 medium Validation: 100% 5 supporting / 3 opposing

✓ For (5)

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 3CLIN 2GENE 3EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
ACE expression in microglia was shown to increase …	Supporting	MECH	J Neuroinflamma…	MEDIUM	2024	-	PMID:38712251	-
Discovery and engineering of an anti-TREM2 antibod…	Supporting	MECH	MAbs	MEDIUM	2022	-	PMID:35921534	-
Sleep deprivation exacerbates microglial reactivit…	Supporting	MECH	Sci Transl Med	MEDIUM	2023	-	PMID:37099634	-
Knock-in models show complex microglial-synapse re…	Opposing	GENE	Mol Neurodegene…	MEDIUM	2021	-	PMID:34266459	-
Microglia-mediated neuroinflammation shows context…	Opposing	CLIN	J Inflamm Res	MEDIUM	2022	-	PMID:35642214	-
Multiregion single-cell analysis identified specif…	Supporting	GENE	Nature Neurosci…	STRONG	2024	-	PMID:39048816	-
TREM2 drives microglia response to amyloid-β via S…	Supporting	GENE	Nature	STRONG	2022	-	PMID:36306735	-
Microglia states and nomenclature remain at a cros…	Opposing	CLIN	Neuron	STRONG	2022	-	PMID:36327895	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in … STRONG▼

Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains

Nature Neuroscience · 2024 · PMID:39048816

ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance MEDIUM

J Neuroinflammation · 2024 · PMID:38712251

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways STRONG

Nature · 2022 · PMID:36306735

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD … MEDIUM▼

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice

MAbs · 2022 · PMID:35921534

Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice MEDIUM

Sci Transl Med · 2023 · PMID:37099634

✗ Opposing Evidence 3

Knock-in models show complex microglial-synapse relationship that does not uniformly support enhancement thera… MEDIUM▼

Knock-in models show complex microglial-synapse relationship that does not uniformly support enhancement therapy

Mol Neurodegener · 2021 · PMID:34266459

Microglia-mediated neuroinflammation shows context-dependent effects that complicate targeted intervention MEDIUM

J Inflamm Res · 2022 · PMID:35642214

Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic … STRONG▼

Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic target states

Neuron · 2022 · PMID:36327895

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-03 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on my research into cell type vulnerability in Alzheimer's Disease using transcriptomic data, I'll generate novel therapeutic hypotheses targeting the most vulnerable cell populations. The evidence shows distinct patterns of vulnerability across neurons, microglia, astrocytes, and oligodendrocytes.

Novel Therapeutic Hypotheses for Cell-Type Specific Alzheimer's Disease Interventions

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Description: Target excitatory neurons in layers II/III and V/VI of the entorhinal cortex and hippocampus that show highest

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

I'll provide a rigorous critique of each hypothesis, identifying weaknesses and providing alternative explanations based on available evidence.

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Specific Weaknesses:

The hypothesis assumes tau pathology is causative rather than correlative. However, extensive clinical failures of tau-targeting therapies suggest tau aggregation may be downstream of other pathogenic processes
Single-cell transcriptomics shows correlation, not causati

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

Based on my research into the druggability, competitive landscape, and clinical reality, here's my comprehensive assessment:

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Druggability Assessment: MODERATE

GSK3β is a well-established drug target with multiple small molecule inhibitors
CDK5 is more challenging - lacks deep binding pockets, making selective inhibition difficult
Cell-type selectivity is the major challenge - no current technology exists for neuron subtyp

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↘

Falling

7d Momentum

▼ 11.0%

Volatility

Medium

0.0202

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
📊	Score Update	$0.526	▼ 17.6%	market_dynamics	2026-04-14 08:05
📄	New Evidence	$0.638	▼ 23.4%	market_dynamics	2026-04-14 04:45
📊	Score Update	$0.833	▲ 36.2%	market_dynamics	2026-04-14 01:57
💬	Debate Round	$0.612	▲ 5.9%	market_dynamics	2026-04-14 01:38
📄	New Evidence	$0.578	▼ 33.7%	market_dynamics	2026-04-14 00:54
💬	Debate Round	$0.871	▲ 97.0%	market_dynamics	2026-04-14 00:49
💬	Debate Round	$0.442	▼ 30.0%	market_dynamics	2026-04-13 23:57
📊	Score Update	$0.632	▼ 12.2%	market_dynamics	2026-04-13 20:31
📄	New Evidence	$0.719		market_dynamics	2026-04-13 20:02

Clinical Trials (12)

0
Active

0
Completed

2,716
Total Enrolled

PHASE2
Highest Phase

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies PHASE2

COMPLETED · NCT03888222 · Georgetown University

26 enrolled · 2019-04-23 · → 2021-08-27

This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half wi

Dementia With Lewy Bodies

Placebo Oral Tablet Bosutinib Oral Tablet

The Signature of Alzheimer's Disease in Subjective Cognitive Decline N/A

RECRUITING · NCT07402161 · IRCCS Policlinico S. Donato

250 enrolled · 2025-10-01 · → 2027-10-01

This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging

Subjective Cognitive Decline (SCD) Subjective Cognitive Complaints (SCCs) Subjective Cognitive Impairment

Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease N/A

COMPLETED · NCT06224920 · Ludwig-Maximilians - University of Munich

140 enrolled · 2017-01-01 · → 2024-01-01

The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there hav

Alzheimer Disease Corticobasal Syndrome

magnetic resonance imaging electroencephalography blood and CSF biomarker

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis N/A

RECRUITING · NCT06339190 · Monash University

1,000 enrolled · 2021-08-01 · → 2025-12

This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level

Neurodegenerative Diseases Dementia

Venepuncture

Clinical, Molecular and Electrophysiological Profiling of Parkinson's Disease: the Role of Non-pharmacological Therapies NA

UNKNOWN · NCT05807581 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

400 enrolled · 2023-06-09 · → 2025-05-30

In Parkinson's disease (PD), direct evidence linking inflammation to the harmful activities of alpha-synuclein (a-syn) aggregates, the disease onset, and its progression is still lacking. This transla

Parkinson Disease

physical activity iTBS

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients PHASE2

COMPLETED · NCT04388254 · Cassava Sciences, Inc.

220 enrolled · 2020-03-24 · → 2023-11-09

A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjec

Alzheimer Disease

Simufilam 100 mg oral tablet Placebo

The Analysis of Gene Variants Related to POCD in Elderly Patients N/A

UNKNOWN · NCT05419596 · Istanbul University

126 enrolled · 2022-07-01 · → 2023-07-01

The pathophysiology of postoperative cognitive dysfunction (POCD) following surgery may be related to Alzheimer's disease. Different studies show that; low levels of glial cell line-derived growth fac

Cognitive Dysfunction

Urologic Surgery

Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder N/A

UNKNOWN · NCT04048603 · Chinese University of Hong Kong

182 enrolled · 2019-05-15 · → 2022-03-31

This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development

REM Sleep Behavior Disorder Neurodegeneration

Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema N/A

UNKNOWN · NCT02227745 · Hospital Juarez de Mexico

60 enrolled · 2014-01 · → 2015-03

Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual

Diabetic Retinopathy Diabetic Macular Edema

Dorzolamide hydrochloride (2%) Placebo Sodium hyaluronate 4mg

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease NA

UNKNOWN · NCT04387812 · Tel-Aviv Sourasky Medical Center

240 enrolled · 2020-06-01 · → 2023-12-31

Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye

Parkinson Disease GBA Gene Mutation Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Xtrodes home PSG system

Ambroxol in Disease Modification in Parkinson Disease PHASE2

COMPLETED · NCT02941822 · University College, London

23 enrolled · 2016-12 · → 2018-04

This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl

Parkinson Disease

Ambroxol

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism PHASE2

COMPLETED · NCT01759888 · Chang Gung Memorial Hospital

49 enrolled · 2011-08 · → 2014-12

The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv

Parkinson's Disease

18F-DTBZ

📚 Cited Papers (8)

Knock-in models related to Alzheimer's disease: synaptic transmission, plaques and the role of microglia.

Molecular neurodegeneration (2022) · PMID:34266459

No extracted figures yet

Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.

J Inflamm Res (2022) · PMID:35642214

No extracted figures yet

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.

mAbs (2022) · PMID:35921534

No extracted figures yet

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.

Cell (2022) · PMID:36306735

No extracted figures yet

Microglia states and nomenclature: A field at its crossroads.

Neuron (2022) · PMID:36327895

No extracted figures yet

Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice.

Science translational medicine (2023) · PMID:37099634

No extracted figures yet

Angiotensin Converting Enzyme (ACE) expression in microglia reduces amyloid β deposition and neurodegeneration by increasing SYK signaling and endolysosomal trafficking.

bioRxiv : the preprint server for biology (2024) · PMID:38712251

No extracted figures yet

Single-cell multiregion dissection of Alzheimer's disease.

Nature (2024) · PMID:39048816

No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data) — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-gap-seaad-v4-20260402065846. What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transcriptomic data from the Allen Brain C …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

KG Entities (61)

ACSL4 AMPK APOE APOE4 APP Alzheimer's Disease Alzheimer's disease C1Q C3 CLDN5 CTSD CX3CR1 DAM DAP12 ERK FSP1 GFAP GPX4 GSK3B HMGCR

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.990 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.950 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration

Score: 0.907 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to Amyloid Clearance

Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

4.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

Pharmacological activation of TREM2-SYK signaling via SYK agonist treatment in 5xFAD mice will reduce amyloid plaque burden by at least 30% compared to vehicle-treated controls within 12 weeks of treatment.

pending conf: 0.72

Expected outcome: Amyloid plaque area fraction will decrease by 30-50% in cortical and hippocampal regions; total insoluble Aβ42 concentration will decline by 40% in brain tissue; microglial P-TREM2 and P-SYK levels will increase 2-3 fold as pharmacodynamic markers.

Falsified by: Amyloid plaque burden shows no significant reduction (p>0.05) or increases by >20% compared to vehicle controls; SYK agonist fails to activate downstream signaling (P-SYK remains at baseline); plaque reduction occurs via TREM2-independent mechanism (persists in TREM2 knockout background).

Method: 5xFAD transgenic mice (n=20/group) will receive daily intraperitoneal SYK agonist (BI213823 or equivalent) or vehicle from 4-6 months of age (during active amyloid deposition). Treatment duration: 12 weeks. Endpoints: (1) Thioflavin-S or 6E10 immunohistochemical quantification of amyloid plaques in cortex/hippocampus, (2) ELISA measurement of TBS-soluble and formic acid-extracted Aβ42, (3) Western blot of P-SYK (Y519/Y520) and P-TREM2 (Y525) from isolated CD11b+ microglia, (4) spatial transcriptomics of microglial activation states. Timeframe: 18 months total (including breeding, treatment, and analysis).

Conditional deletion of SYK specifically in microglia (CX3CR1-CreERT2;SYKflox/flox) will completely abrogate the neuroprotective effect of TREM2 overexpression in APP/PS1 mice, resulting in amyloid burden and cognitive deficits equivalent to APP/PS1 controls.

pending conf: 0.65

Expected outcome: APP/PS1;TREM2-TG;Sykk/k mice will show equivalent amyloid plaque coverage (~15-20% area in cortex) to APP/PS1 controls; Morris water maze will reveal no improvement in spatial memory (escape latency >40 seconds on day 4); microglial transcriptomics will show absent expression of TREM2-dependent genes (APOE, LPL, CLEC7A) despite TREM2 overexpression.

Falsified by: APP/PS1;TREM2-TG;Sykk/k mice show >30% reduction in amyloid plaques compared to APP/PS1 controls; cognitive performance significantly improves despite SYK deletion; TREM2 overexpression continues to activate downstream gene expression programs in the absence of SYK.

Method: Cross CX3CR1-CreERT2 mice with SYKflox/flox mice and APP/PS1;TREM2-Transgenic mice to generate four genotypes: (1) APP/PS1 (control), (2) APP/PS1;TREM2-TG (positive control for TREM2 benefit), (3) APP/PS1;Sykk/k (TREM2 intact, SYK deleted), (4) APP/PS1;TREM2-TG;Sykk/k (critical test). Tamoxifen administration at P30-P60 achieves microglial-specific recombination. Treatment: 8-month longitudinal study with tamoxifen at P45. Endpoints: (1) amyloid plaque quantification at 8 months, (2) 6-day Morris water maze at 7.5 months, (3) scRNA-seq of sorted microglia (CD45int/CD11b+) at 8 months assessing TREM2-SYK target gene expression. Timeframe: 24 months total.

Knowledge Subgraph (200 edges)

associated with (11)

reactive_astrocyte→astrocyteDAM→microgliaOPC→oligodendrocyteMAPT→GSK3BACSL4→Alzheimer's Disease

▸ Show 6 more

SIRT3→Alzheimer's DiseaseSLC16A1→Alzheimer's DiseaseACSL4→alzheimer_s_diseaseSIRT3→alzheimer_s_diseaseSLC16A1→alzheimer_s_diseasemicroglia→Alzheimer's disease

co associated with (5)

SIRT3→PINK1SLC16A1→MCT4ACSL4→SLC16A1ACSL4→SIRT3SIRT3→SLC16A1

co discussed (167)

TREM2→C3TREM2→PARP1C3→PARP1C3→APOEPARP1→APOE

▸ Show 162 more

PVALB→SIRT3PVALB→PDGFRBPVALB→SREBF2PVALB→GFAPPVALB→SLC16A1PVALB→ACSL4PVALB→CLDN5PVALB→MMP9SIRT3→PDGFRBSIRT3→SREBF2SIRT3→GFAPSIRT3→SLC16A1SIRT3→ACSL4SIRT3→CLDN5SIRT3→MMP9PDGFRB→SREBF2PDGFRB→GFAPPDGFRB→SLC16A1PDGFRB→ACSL4PDGFRB→CLDN5PDGFRB→MMP9SREBF2→GFAPSREBF2→SLC16A1SREBF2→ACSL4SREBF2→CLDN5SREBF2→MMP9GFAP→SLC16A1GFAP→ACSL4GFAP→CLDN5SLC16A1→ACSL4SLC16A1→CLDN5SLC16A1→MMP9ACSL4→CLDN5ACSL4→MMP9CLDN5→MMP9TREM2→SIRT3TREM2→TFRCTREM2→GFAPTREM2→PPARGC1ATREM2→SLC16A1TREM2→GPX4TREM2→TFAMTREM2→ACSL4SIRT3→TFRCSIRT3→PPARGC1ASIRT3→GPX4SIRT3→TFAMSIRT3→CX3CR1TFRC→GFAPTFRC→PPARGC1ATFRC→SLC16A1TFRC→GPX4TFRC→TFAMTFRC→CX3CR1TFRC→ACSL4GFAP→PPARGC1AGFAP→CX3CR1PPARGC1A→SLC16A1PPARGC1A→GPX4PPARGC1A→CX3CR1PPARGC1A→ACSL4SLC16A1→GPX4SLC16A1→TFAMSLC16A1→CX3CR1GPX4→CX3CR1GPX4→ACSL4TFAM→CX3CR1TFAM→ACSL4CX3CR1→ACSL4APOE→C3APOE→PARP1ACSL4→PDGFRBACSL4→GFAPACSL4→SIRT3ACSL4→SLC16A1ACSL4→PVALBACSL4→SREBF2ACSL4→HMGCRPDGFRB→SIRT3PDGFRB→PVALBPDGFRB→HMGCRMMP9→GFAPMMP9→SIRT3MMP9→SLC16A1MMP9→CLDN5MMP9→PVALBMMP9→SREBF2MMP9→HMGCRGFAP→SIRT3GFAP→PVALBGFAP→SREBF2GFAP→HMGCRSIRT3→PVALBSIRT3→HMGCRSLC16A1→PVALBSLC16A1→SREBF2SLC16A1→HMGCRCLDN5→PVALBCLDN5→SREBF2CLDN5→HMGCRPVALB→HMGCRSREBF2→HMGCRACSL4→TFRCACSL4→PPARGC1AACSL4→TFAMACSL4→TREM2TFRC→SIRT3TFRC→TREM2PPARGC1A→GFAPPPARGC1A→TREM2TFAM→GFAPTFAM→SIRT3TFAM→SLC16A1TFAM→TREM2TFAM→GPX4SIRT3→TREM2CX3CR1→SLC16A1CX3CR1→GPX4SLC16A1→TREM2SLC16A1→SIRT3SLC16A1→GFAPSLC16A1→PDGFRBCLDN5→ACSL4CLDN5→SIRT3CLDN5→GFAPCLDN5→PDGFRBHMGCR→ACSL4HMGCR→PVALBHMGCR→SIRT3HMGCR→MMP9HMGCR→GFAPHMGCR→SREBF2HMGCR→PDGFRBMMP9→PDGFRBGFAP→PDGFRBSREBF2→PDGFRBSLC16A1→PPARGC1ASLC16A1→TFRCCX3CR1→SIRT3CX3CR1→PPARGC1ACX3CR1→TFRCCX3CR1→TFAMGPX4→SIRT3GPX4→PPARGC1AGPX4→TFRCGPX4→GFAPPPARGC1A→TFRCGPX4→TREM2ACSL4→TNFSLC7A11→TREM2ACSL4→APOEACSL4→APOE4ACSL4→C1QAPOE4→C1QAPOE4→GPX4GPX4→TNFACSL4→APPACSL4→TAUFSP1→GPX4DAP12→ERKCTSD→CX3CR1AMPK→TREM2

dysregulates (1)

APOE4→cholesterol_metabolism

implicated in (6)

ACSL4→neurodegenerationSLC16A1→neurodegenerationoligodendrocyte→Alzheimer's diseaseneuron→Alzheimer's diseaseexcitatory_neuron→Alzheimer's disease

▸ Show 1 more

inhibitory_neuron→Alzheimer's disease

Mechanism Pathway for TREM2

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    TREM2["TREM2"] -->|co discussed| C3["C3"]
    TREM2_1["TREM2"] -->|co discussed| PARP1["PARP1"]
    TREM2_2["TREM2"] -->|co discussed| SIRT3["SIRT3"]
    TREM2_3["TREM2"] -->|co discussed| TFRC["TFRC"]
    TREM2_4["TREM2"] -->|co discussed| GFAP["GFAP"]
    TREM2_5["TREM2"] -->|co discussed| PPARGC1A["PPARGC1A"]
    TREM2_6["TREM2"] -->|co discussed| SLC16A1["SLC16A1"]
    TREM2_7["TREM2"] -->|co discussed| GPX4["GPX4"]
    TREM2_8["TREM2"] -->|co discussed| TFAM["TFAM"]
    TREM2_9["TREM2"] -->|co discussed| ACSL4["ACSL4"]
    ACSL4_10["ACSL4"] -->|co discussed| TREM2_11["TREM2"]
    TFRC_12["TFRC"] -->|co discussed| TREM2_13["TREM2"]
    PPARGC1A_14["PPARGC1A"] -->|co discussed| TREM2_15["TREM2"]
    TFAM_16["TFAM"] -->|co discussed| TREM2_17["TREM2"]
    SIRT3_18["SIRT3"] -->|co discussed| TREM2_19["TREM2"]
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style C3 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_1 fill:#ce93d8,stroke:#333,color:#000
    style PARP1 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_2 fill:#ce93d8,stroke:#333,color:#000
    style SIRT3 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_3 fill:#ce93d8,stroke:#333,color:#000
    style TFRC fill:#ce93d8,stroke:#333,color:#000
    style TREM2_4 fill:#ce93d8,stroke:#333,color:#000
    style GFAP fill:#ce93d8,stroke:#333,color:#000
    style TREM2_5 fill:#ce93d8,stroke:#333,color:#000
    style PPARGC1A fill:#ce93d8,stroke:#333,color:#000
    style TREM2_6 fill:#ce93d8,stroke:#333,color:#000
    style SLC16A1 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_7 fill:#ce93d8,stroke:#333,color:#000
    style GPX4 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_8 fill:#ce93d8,stroke:#333,color:#000
    style TFAM fill:#ce93d8,stroke:#333,color:#000
    style TREM2_9 fill:#ce93d8,stroke:#333,color:#000
    style ACSL4 fill:#ce93d8,stroke:#333,color:#000
    style ACSL4_10 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_11 fill:#ce93d8,stroke:#333,color:#000
    style TFRC_12 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_13 fill:#ce93d8,stroke:#333,color:#000
    style PPARGC1A_14 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_15 fill:#ce93d8,stroke:#333,color:#000
    style TFAM_16 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_17 fill:#ce93d8,stroke:#333,color:#000
    style SIRT3_18 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_19 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 TREM2 — PDB 6YXY Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

neurodegeneration | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Edit History

Action	Actor	Timestamp	Reason	Changes
update	unknown	2026-04-16T10:17	No reason provided	Changes recorded
update	unknown	2026-04-16T10:17	No reason provided	Changes recorded
update	unknown	2026-04-16T10:17	No reason provided	Changes recorded
update	unknown	2026-04-16T10:17	No reason provided	Changes recorded

View full edit history (JSON)

Microglial TREM2-SYK Pathway Enhancement

Hypotheses from Same Analysis (8)

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

Dimension Scores

✓ Supporting Evidence 5

✗ Opposing Evidence 3

Novel Therapeutic Hypotheses for Cell-Type Specific Alzheimer's Disease Interventions

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Critical Evaluation of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Practical Feasibility Assessment of Cell-Type Specific Alzheimer's Therapeutic Hypotheses

1. Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes

Price History

Clinical Trials (12)

📚 Cited Papers (8)

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Hypotheses from Same Analysis (8)

🧬 Same Target Gene / Disease (30)

KG Entities (61)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (200 edges)

associated with (11)

co associated with (5)

co discussed (167)

dysregulates (1)

implicated in (6)

investigated in (1)

involved in (2)

maintains (1)

participates in (3)

performs (1)

regulates (1)

vulnerable to (1)

Mechanism Pathway for TREM2

3D Protein Structure

Source Analysis

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Community Feedback

Edit History